Hjem › Myelofibrose › Kansas
Myelofibrose kliniske forsøg i Kansas
6 studier for Myelofibrose søger deltagere på steder i Kansas.
Officiel studietekst (engelsk)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06661915A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Kansas Medical Center, Kansas City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06343805Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
- The University of Kansas Cancer Center, Fairway
RekruttererTidlig fase 1Frivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 6. maj 2026 · NCT06414681A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. apr. 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
RekruttererFase 2
Alder 18 til 66 · Alle køn · Opdateret 17. mar. 2026 · NCT06859424Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- University of Kansas Cancer Center - Westwood, Westwood
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT06479135Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.